Cite
HARVARD Citation
Dalovisio, A. et al. (n.d.). P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA. HemaSphere. pp. 788-789. [Online].